We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.34B
AUM Growth
+$140M
Cap. Flow
+$87.9M
Cap. Flow %
3.75%
Top 10 Hldgs %
23.56%
Holding
168
New
20
Increased
60
Reduced
15
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$65.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$38.6M
3
HCA icon
HCA Healthcare
HCA
+$36.9M
4
COR icon
Cencora
COR
+$28.3M
5
DVA icon
DaVita
DVA
+$24M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$67.4M
2
CI icon
Cigna
CI
+$65.2M
3
MRK icon
Merck
MRK
+$47.9M
4
JNJ icon
Johnson & Johnson
JNJ
+$27.9M
5
WTW icon
Willis Towers Watson
WTW
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.66%
2 Financials 1.72%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KA
126
DELISTED
Kineta, Inc. Common Stock
KA
$3.21M 0.14%
4,821
– –
RARX
127
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.19M 0.14%
600,000
– –
NBRV
128
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.14M 0.13%
2,500
– –
AGN
129
DELISTED
Allergan plc
AGN
$2.97M 0.13%
+17,665
New +$2.96M
CORV
130
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2.78M 0.12%
1,200,000
– –
ACET icon
131
Adicet Bio
ACET
$74.7M
$2.63M 0.11%
+2,455
New +$4.5M
DBVT
132
DBV Technologies
DBVT
$847M
$1.68M 0.07%
7,300
– –
MCRB icon
133
Seres Therapeutics
MCRB
$48.9M
$1.61M 0.07%
11,000
– –
RYTM icon
134
Rhythm Pharmaceuticals
RYTM
$7.96B
$1.42M 0.06%
71,500
– –
CDTX
135
DELISTED
Cidara Therapeutics
CDTX
$1.2M 0.05%
15,000
– –
SCYX icon
136
SCYNEXIS
SCYX
$52M
$1.1M 0.05%
10,250
+750
+8% +$103K
SLDB icon
137
Solid Biosciences
SLDB
$900M
$938K 0.04%
+8,333
New +$2.81M
CHMA
138
DELISTED
Chiasma, Inc. Common Stock
CHMA
$788K 0.03%
525,000
– –
INFI
139
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$567K 0.02%
270,000
– –
KURA icon
140
Kura Oncology
KURA
$850M
$497K 0.02%
+26,500
New +$516K
CI icon
141
Cigna
CI
$74.6B
– –
-321,000
Closed -$65.2M
DARE icon
142
Dare Bioscience
DARE
$21M
– –
-5,208
Closed -$135K
HQY icon
143
HealthEquity
HQY
$8.75B
– –
-195,000
Closed -$9.1M
IRWD icon
144
Ironwood Pharmaceuticals
IRWD
$714M
– –
-268,650
Closed -$3.37M
JNJ icon
145
Johnson & Johnson
JNJ
$625B
– –
-200,000
Closed -$27.9M
MRK icon
146
Merck
MRK
$318B
– –
-891,534
Closed -$47.9M
STE icon
147
Steris
STE
$23.1B
– –
-74,000
Closed -$6.47M
WTW icon
148
Willis Towers Watson
WTW
$32B
– –
-123,000
Closed -$18.5M
ATYR
149
aTyr Pharma
ATYR
$50.1M
– –
-33,929
Closed -$1.66M
ALPN
150
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-150,000
Closed -$1.68M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rock Springs Capital Management held 168 positions worth $2.34B, up 6.4% from $2.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $87.9M of net new capital in Q1 2018, opening 20 new positions and adding to 60 existing holdings. Its largest new stake was AbbVie: 600,000 shares worth $56.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was PRA Health Sciences, Inc., an estimated $7.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2018 buy was AbbVie: 600,000 shares worth $56.8M.
  • Rock Springs Capital Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $38.6M increase.
  • Rock Springs Capital Management's biggest Q1 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $7.33M.
  • Rock Springs Capital Management fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $67.4M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $2.34B portfolio in Q1 2018.
  • Rock Springs Capital Management opened 20 new positions and closed 19 in Q1 2018.
  • Rock Springs Capital Management's portfolio value rose 6.4% quarter-over-quarter to $2.34B.

Based on Rock Springs Capital Management's 13F filing for Q1 2018, filed 15 May 2018.